Conan MacDougall
@conanmacdougall.bsky.social
Professor of Clinical Pharmacy @UCSFPharmacy, Infectious Diseases Pharmacist | Evidence-informed Instructional Design, Infectious Diseases Pharmacotherapy | Hiking, Backpacking, Boston Celtics Basketball
I first read it as “Epicpocalypse” and thought it was a game about adopting EPIC as your EMR and thought “hey that’s spot-on!”
September 29, 2025 at 10:49 PM
I first read it as “Epicpocalypse” and thought it was a game about adopting EPIC as your EMR and thought “hey that’s spot-on!”
“You say you’ve ’done your research’ but have you done your ‘Responsible Conduct of Research’?”
September 26, 2025 at 1:46 AM
“You say you’ve ’done your research’ but have you done your ‘Responsible Conduct of Research’?”
Predict it will take at least a decade until people stop saying “positives are it works better, negatives are it’s a lot more expensive that vanco”. See Zolid, Line. @pharmermeg.bsky.social
September 8, 2025 at 10:00 PM
Predict it will take at least a decade until people stop saying “positives are it works better, negatives are it’s a lot more expensive that vanco”. See Zolid, Line. @pharmermeg.bsky.social
we lack good PK/PD models of what “mop-up” looks like. It would be a lot more reassuring to have a “mop-up” target exposure. This paper (h/t Nav Narayan) being an example (journals.asm.org/doi/10.1128/...). Important as new PO carbapenems hit the market.
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model | Antimi...
Tebipenem is an orally bioavailable carbapenem in development for the treatment of
patients with complicated urinary tract infections. Herein, we describe the results
of studies designed to evaluate t...
journals.asm.org
September 3, 2025 at 6:45 PM
we lack good PK/PD models of what “mop-up” looks like. It would be a lot more reassuring to have a “mop-up” target exposure. This paper (h/t Nav Narayan) being an example (journals.asm.org/doi/10.1128/...). Important as new PO carbapenems hit the market.
Yeah that was one of my main takeaways- TID or QID is less fun than BID but is in line with the Pk and PK/PD of these drugs and with shortened overall durations is usually only like 3-5 days of completion tx. I think the main argument vs more aggressive dosing is “this is just mop-up” but 1/
September 3, 2025 at 6:45 PM
Yeah that was one of my main takeaways- TID or QID is less fun than BID but is in line with the Pk and PK/PD of these drugs and with shortened overall durations is usually only like 3-5 days of completion tx. I think the main argument vs more aggressive dosing is “this is just mop-up” but 1/
(Just to clear up any confusion people
might have, proper attribution for this book would be like “Jason Gallagher (ft. Conan MacDougall”))
might have, proper attribution for this book would be like “Jason Gallagher (ft. Conan MacDougall”))
August 4, 2025 at 8:08 PM
(Just to clear up any confusion people
might have, proper attribution for this book would be like “Jason Gallagher (ft. Conan MacDougall”))
might have, proper attribution for this book would be like “Jason Gallagher (ft. Conan MacDougall”))
Look who I am to question what ChatGPT decides?
August 4, 2025 at 2:41 PM
Look who I am to question what ChatGPT decides?